A Phase 4 interventional study of Statin in Ischemic Stroke, sponsored by Hyogo Medical University. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-02-27.
Sponsored by Hyogo Medical University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing statins in Ischemic Stroke — 10 open to participants now, 10 under way, 3 of them phase 3. A drug class: Statins · Ischemic Stroke.
Among the 21 studies testing statins in Ischemic Stroke, this one is the 15th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 4, and was the 8th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →10 of the 21 studies testing statins in Ischemic Stroke are open now, in 4 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
Duan Chuanzhi · Sites in China
Ages 18–75
Kafrelsheikh University · Sites in Egypt
Ages 18–75
Kafrelsheikh University · Sites in Egypt
Ages 18–75
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 8 · Phase 4 9
First in 2004; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 270 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 354 across the 21 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 21 has an industry lead sponsor. The 10 most frequent:
Hyogo Medical University is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Hyogo Medical University has 5 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies testing statins in Ischemic Stroke that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908875Phase 3First Affiliated Hospital of Wannan Medical CollegeUpfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. | 2027-09-30 |
| NCT05589454Sichuan Provincial People's HospitalIntracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing statins in Ischemic Stroke, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigators will study whether immediate statin treatment after the onset of stroke is beneficial on the neurological protection
It is much more important in Japan than Western to improve the prognosis after stroke because the prevalence and mortality rate of stroke in Japan is about 3-4 times as those of acute myocardial infarction. Investigators will study whether immediate statin treatment after the onset of stroke is beneficial on the neurological protection since most of previous studies with statins just showed the preventive effects from onset of primary or recurrent cerebral infarction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission
Drug: Statin
Not start or withdraw Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment for a weak after admission.
Drug: Statin
Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
Also known as: Atorvastatin, Pitavastain, Rosuvastatin
modified Rankin Scale
Scale range from 0 \[no symptom\] to 6 \[dead\]
Time frame: 12 weeks from stroke onset
Ran from Sep 2015 to primary completion in Dec 2016, 15 months.
Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's 15 months is below that.
Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Statins
Hyogo Medical University